- Home
- NVCR vs BHVN Comparison
NVCR vs BHVN Comparison
Compare NVCR & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- BHVN
- Stock Information
- Founded
- NVCR 2000
- BHVN 2013
- Country
- NVCR Switzerland
- BHVN United States
- Employees
- NVCR N/A
- BHVN N/A
- Industry
- NVCR Medical/Dental Instruments
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- NVCR Health Care
- BHVN Health Care
- Exchange
- NVCR Nasdaq
- BHVN Nasdaq
- Market Cap
- NVCR 1.9B
- BHVN 1.9B
- IPO Year
- NVCR 2015
- BHVN 2017
- Fundamental
- Price
- NVCR $17.60
- BHVN $14.01
- Analyst Decision
- NVCR Buy
- BHVN Strong Buy
- Analyst Count
- NVCR 7
- BHVN 14
- Target Price
- NVCR $32.43
- BHVN $58.85
- AVG Volume (30 Days)
- NVCR 1.4M
- BHVN 1.9M
- Earning Date
- NVCR 07-24-2025
- BHVN 08-07-2025
- Dividend Yield
- NVCR N/A
- BHVN N/A
- EPS Growth
- NVCR N/A
- BHVN N/A
- EPS
- NVCR N/A
- BHVN N/A
- Revenue
- NVCR $621,711,000.00
- BHVN N/A
- Revenue This Year
- NVCR $5.56
- BHVN $3.00
- Revenue Next Year
- NVCR $9.19
- BHVN $59.97
- P/E Ratio
- NVCR N/A
- BHVN N/A
- Revenue Growth
- NVCR 18.27
- BHVN N/A
- 52 Week Low
- NVCR $14.17
- BHVN $13.75
- 52 Week High
- NVCR $34.13
- BHVN $55.70
- Technical
- Relative Strength Index (RSI)
- NVCR 49.74
- BHVN 41.34
- Support Level
- NVCR $16.81
- BHVN $13.75
- Resistance Level
- NVCR $18.59
- BHVN $15.09
- Average True Range (ATR)
- NVCR 0.74
- BHVN 0.71
- MACD
- NVCR 0.08
- BHVN 0.14
- Stochastic Oscillator
- NVCR 56.18
- BHVN 20.56
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.